Differential Effector Response of Amnion- and Adipose-Derived Mesenchymal Stem Cells to Inflammation; Implications for Intradiscal Therapy.
Borem R., Madeline A., Bowman M., Gill S., Tokish J., Mercuri J.
Prospective Study on Disc Degeneration, Chronic Inflammation, published in J Orthop Res (2019) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Orthop Res (2019)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 31287173
- DOI
- 10.1002/jor.24412
- Citations
- 21
Abstract (original English)
Intervertebral disc degeneration (IVDD) is a progressive condition marked by tissue destruction and inflammation. The therapeutic effector functions of mesenchymal stem cells (MSCs) makes them an attractive therapy for patients with IVDD. While several sources of MSCs exist, the optimal choice for use in the inflamed IVD remains a significant question. Adipose (AD)- and amnion (AM)-derived MSCs have several advantages compared with other sources, however, no study has directly compared the impact of IVDD inflammation on their effector functions. Human MSCs were cultured in media with or without supplementation of interleukin-1β (IL-1β) and tumor necrosis factor-α at concentrations reportedly produced by IVDD cells. MSC proliferation and production of pro- and anti-inflammatory cytokines were quantified following 24 and 48 h of culture. Additionally, the osteogenic and chondrogenic potential of AD- and AM-MSCs was characterized via histology and biochemical analysis following 28 days of culture. In inflammatory culture, AM-MSCs produced significantly more anti-inflammatory IL-10 (14.47 ± 2.39 pg/ml; p = 0.004) and larger chondrogenic pellets (5.67 ± 0.26 mm 2 ; p = 0.04) with greater percent area staining positively for glycosaminoglycan (82.03 ± 3.26%; p < 0.001) compared with AD-MSCs (0.00 ± 0.00 pg/ml; 2.76 ± 0.18 mm 2 ; 34.75 ± 2.49%; respectively). Conversely, AD-MSCs proli
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level AMeta-analysisEurope PMC
Platelet-Rich Plasma vs. Mesenchymal Stem Cells for Lumbar Disc Degeneration: A Systematic Review and Meta-Analysis
Meta-analysis on Disc Degeneration, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewEurope PMC
Role of Platelet-Rich Plasma (PRP) in the Management of Stage III and IV Degenerative Disc Disease
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
- 2025
Cureus1 citations - Level AMeta-analysisPubMed
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Meta-analysis with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine1 citations - Level ASystematic ReviewEurope PMC
Sirtuins in intervertebral disc degeneration: current understanding
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Mol Med (2024) — summary generated from the PubMed abstract.
- 2024
Mol Med11 citations - Level ASystematic ReviewEurope PMC
A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis
Systematic Review on Back Pain, Disc Degeneration, published in JOR Spine (2024) — summary generated from the PubMed abstract.
- 2024
JOR Spine22 citations